Quintiles Launches New Capabilities in Asia

Quintiles has launched two new services, Strategic Drug Development and Consulting at Quintiles, aimed at helping biopharmaceutical companies navigate the Asian market.

The new Strategic Drug Development organization was established to help biopharma companies design and implement drug development strategies that take into account the Asia product commercialization opportunity and regulatory hurdles before the standardized development process.

Also, Consulting at Quintiles aims to help customers by linking business strategy, industry expertise and data-driven insights within six practice areas. This combination of strategy and operations across regulatory, clinical and commercial, aims to provide comprehensive guidance on how to gain value in Asian assets and markets.

“Beyond simply helping customers meet their needs in the region, our goals are to help define them,” said Amar Kureishi, chief medical officer and head of Strategic Drug Development for Quintiles in Asia. “Today marks the formal service launch, yet our world-class team already has worked with customers on more than 15 projects to transform their development aspirations into reality.”

“Drug development and commercialization in Asia will benefit greatly from new, strategic approaches,” said Christian Gabel, Ph.D., vice president and head of Consulting at Quintiles Asia. “Quintiles draws on expertise and lessons learned from 30 years of product development and commercialization in the west to bring differentiated approaches to companies in the east. We are introducing new strategic consulting services to the Asia market, such as our Health Technology Assessment that deploys social networking techniques to anticipate shifts in global market access and our Market Accelerator end-to-end solution to transpose local drugs to global markets.”